- Home
- NKTR vs SANA Comparison
NKTR vs SANA Comparison
Compare NKTR & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- SANA
- Stock Information
- Founded
- NKTR 1990
- SANA 2018
- Country
- NKTR United States
- SANA United States
- Employees
- NKTR N/A
- SANA N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- NKTR Health Care
- SANA Health Care
- Exchange
- NKTR Nasdaq
- SANA Nasdaq
- Market Cap
- NKTR 1.2B
- SANA 983.4M
- IPO Year
- NKTR 1994
- SANA 2021
- Fundamental
- Price
- NKTR $57.96
- SANA $4.12
- Analyst Decision
- NKTR Strong Buy
- SANA Strong Buy
- Analyst Count
- NKTR 6
- SANA 6
- Target Price
- NKTR $91.67
- SANA $8.00
- AVG Volume (30 Days)
- NKTR 1.2M
- SANA 3.8M
- Earning Date
- NKTR 11-06-2025
- SANA 11-07-2025
- Dividend Yield
- NKTR N/A
- SANA N/A
- EPS Growth
- NKTR N/A
- SANA N/A
- EPS
- NKTR N/A
- SANA N/A
- Revenue
- NKTR $74,934,000.00
- SANA N/A
- Revenue This Year
- NKTR N/A
- SANA N/A
- Revenue Next Year
- NKTR N/A
- SANA N/A
- P/E Ratio
- NKTR N/A
- SANA N/A
- Revenue Growth
- NKTR N/A
- SANA N/A
- 52 Week Low
- NKTR $6.48
- SANA $1.26
- 52 Week High
- NKTR $62.95
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- NKTR 65.18
- SANA 68.83
- Support Level
- NKTR $57.50
- SANA $3.28
- Resistance Level
- NKTR $62.82
- SANA $3.58
- Average True Range (ATR)
- NKTR 3.73
- SANA 0.23
- MACD
- NKTR -0.77
- SANA 0.11
- Stochastic Oscillator
- NKTR 56.85
- SANA 90.98
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.